Covidien plc (COV), Pfizer Inc. (PFE): Buybacks Could Keep Up This Stock’s Momentum

Page 1 of 2

Dublin-based pharmaceutical and medical device company Covidien plc (NYSE:COV) recently announced that it had authorized a share buyback program that could be worth up to $2 billion. This announcement comes just a few months after the company boosted its dividend by more than 15 percent and issued several quarters of solid earnings. To make matters even more interesting, the company appears to be nearing the completion of its long-awaited spin-off of Mallinckrodt Pharmaceuticals (MKG – not yet listed).

Covidien plc (COV)

Taken together, these factors appear to make a convincing case for Covidien plc (NYSE:COV)’s short-term performance. Despite exhibiting market-beating performance thus far this year, Covidien plc (NYSE:COV) is perennially overlooked in favor of larger and more “popular” medical firms like Pfizer Inc. (NYSE:PFE) and Medtronic, Inc. (NYSE:MDT) . If the company can translate these positive signs into lasting momentum for its stock, those who take long positions in Covidien plc (NYSE:COV) at these levels could be handsomely rewarded.

About Covidien

Covidien is a diversified manufacturer and distributor of various medical devices and products that can be used in institutional and private settings. It specializes in producing devices that can be used during surgery, including surgical staplers, vessel-sealing products, and laproscopic equipment for minimally invasive procedures. Covidien plc (NYSE:COV)also makes a number of tissue repair and wound care products and devices. Separately, Covidien plc (NYSE:COV) engages in a number of pharmaceutical development operations and currently spends about 4 percent of its gross revenues on research. Its signature pharmaceutical products include various pain relief drugs and imaging agents. Covidien earned $1.9 billion on gross 2012 revenues of about $12 billion.

Competitors

It goes without saying that the pharmaceutical and medical device industries are frighteningly competitive. Covidien has several major pharmaceutical competitors, including companies like Pfizer Inc. (NYSE:PFE) and Merck (MRK). Like Covidien, Pfizer Inc. (NYSE:PFE) engages in the development of a variety of pharmaceutical products. Since it focuses specifically on drugs and drug delivery systems, Pfizer Inc. (NYSE:PFE) may be better positioned to compete in this market. However, it has been widely reported that the company faces a “patent cliff” and will need to work to replenish its development pipeline. With revenues of around $59 billion, Pfizer Inc. (NYSE:PFE) is several times larger than Covidien.

Covidien also competes with medical device manufacturers like Medtronic. Many of Medtronic’s most important devices deal with various cardiovascular issues, including arrhythmia, heart failure, fibrillation and other problems. The company also produces devices that are designed to combat kidney failure and other renal issues. Medtronic is one of the world’s largest providers of musculoskeletal therapy devices and surgical aids. With revenues of around $16.5 billion, Medtronic is roughly the same size as Covidien.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!